Friday, March 22, 2019 8:19:19 PM
Recent OGEN News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:14:33 PM
- Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards • Business Wire • 04/19/2024 09:50:00 PM
- Oragenics, Inc. Files 10K and Provides Company Update • Business Wire • 04/01/2024 01:05:00 PM
- Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion • Business Wire • 03/18/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/06/2024 09:24:29 PM
- Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion • Business Wire • 03/05/2024 12:45:00 PM
- Oragenics Announces Closing of Public Offering • Business Wire • 03/01/2024 09:04:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:41:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:03:04 PM
- Oragenics Announces Pricing of Public Offering • Business Wire • 02/28/2024 02:25:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/27/2024 10:09:12 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 10:04:34 PM
- Oragenics Announces Proposed Public Offering • Business Wire • 02/27/2024 09:33:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/13/2024 01:06:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:45:18 PM
- Oragenics, Inc. Announces Leadership Transition • Business Wire • 02/12/2024 09:41:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:18 PM
- Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement • Business Wire • 02/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:00:23 PM
- Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion • Business Wire • 02/05/2024 01:00:00 PM
- Oragenics Announces Termination of At-The-Market Offering Program • Business Wire • 01/23/2024 10:34:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:18:59 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 10:30:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 02:10:51 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM